Menlo Therapeutics (FOMX) Stock Price, News & Analysis

Company Overview

Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 for the treatment of moderate-to-severe acne vulgaris; and FMX110 for the treatment of papulopustular rosacea. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; LEO Pharma A/S; Mylan N.V.; and Actavis plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Key Stats

• Today's Range: $2.99 to $2.99
• 50-Day Range: $2.99 to $2.99
• 52-Week Range: $1.97 to $4.84
• Volume: N/A
• Average Volume: 518,350 shs
• Market Capitalization: $184.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FOMX Stock Analysis - Frequently Asked Questions

How were Menlo Therapeutics' earnings last quarter?

Menlo Therapeutics Inc. (NASDAQ:FOMX) issued its earnings results on Monday, November, 11th. The specialty pharmaceutical company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.07.

What other stocks do shareholders of Menlo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Menlo Therapeutics investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Amarin (AMRN), Bristol Myers Squibb (BMY), Sangamo Therapeutics (SGMO), Anavex Life Sciences (AVXL) and CRISPR Therapeutics (CRSP).

Company Calendar

• Last Earnings: 11/11/2019
• Today: 6/27/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medicinals & Botanicals
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FOMX
• CIK: 1606645
• Web: www.foamix.com
• Phone: 972-8931-6233
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.16 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -100.58%
• Return on Assets: -81.39%

Debt

• Debt-to-Equity Ratio: 0.24
• Current Ratio: 5.72
• Quick Ratio: 5.72

Sales & Book Value

• Annual Sales: $3.60 million
• Price / Sales: 51.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.70 per share
• Price / Book: 1.76

Miscellaneous

• Outstanding Shares: 61,580,000
• Free Float: N/A
• Market Cap: $184.12 million
• Optionable: Optionable
• Beta: 1.66